Published in Mov Disord on April 30, 2007
What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol (2014) 1.11
Prospective memory deficits are associated with poorer everyday functioning in Parkinson's disease. J Int Neuropsychol Soc (2012) 0.89
Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer. J Pain Symptom Manage (2012) 0.88
A pilot study to identify correlates of intentional versus unintentional nonadherence to analgesic treatment for cancer pain. Pain Manag Nurs (2011) 0.84
The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial. Trials (2011) 0.84
Estimates of adherence to treatment of vivax malaria. Malar J (2014) 0.83
Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. BMC Clin Pharmacol (2012) 0.82
Medication non-adherence in essential tremor. Parkinsonism Relat Disord (2014) 0.76
Pill counts, self reports, and electronic monitoring -- which is most informative in the study of therapy adherence in Parkinson's disease? Mov Disord (2007) 0.75
Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease. NPJ Parkinsons Dis (2017) 0.75
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Physical abuse and neglect of children. Lancet (2007) 2.37
Benefits and harms associated with the practice of bed sharing: a systematic review. Arch Pediatr Adolesc Med (2007) 2.34
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Applying a phase II futility study design to therapeutic stroke trials. Stroke (2005) 1.89
Acculturation and diabetes among Hispanics: evidence from the 1999-2002 National Health and Nutrition Examination Survey. Public Health Rep (2006) 1.84
Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A (2007) 1.80
Variation in estimated ozone-related health impacts of climate change due to modeling choices and assumptions. Environ Health Perspect (2012) 1.74
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol (2005) 1.67
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work (2013) 1.59
Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet (2006) 1.50
Evaluation of a new pulse oximeter sensor. Am J Crit Care (2007) 1.50
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics (2005) 1.47
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med (2005) 1.44
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Contemporary outcome measures in acute stroke research: choice of primary outcome measure and statistical analysis of the primary outcome in acute stroke trials. Stroke (2012) 1.39
Quasi-likelihood estimation for relative risk regression models. Biostatistics (2005) 1.31
Development of a measure to assess patient trust in medical researchers. Ann Fam Med (2006) 1.30
Correlates and predictors of colorectal cancer screening among male automotive workers. Cancer Epidemiol Biomarkers Prev (2007) 1.22
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology (2011) 1.21
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol (2012) 1.20
A coronary heart disease risk score based on patient-reported information. Am J Cardiol (2007) 1.19
Recruiting older African American men to a cancer screening trial (the AAMEN Project). Gerontologist (2003) 1.16
Intention to be screened over time for colorectal cancer in male automotive workers. Cancer Epidemiol Biomarkers Prev (2003) 1.13
Recruitment of African Americans with type 2 diabetes to a randomized controlled trial using three sources. Ethn Health (2002) 1.12
Examining the role of perceived susceptibility on colorectal cancer screening intention and behavior. Ann Behav Med (2010) 1.12
The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord (2008) 1.12
Child protection: a neglected area of pediatric residency training. Child Abuse Negl (2004) 1.11
Retention of under-represented minorities in drug abuse treatment studies. Clin Trials (2009) 1.10
Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol (2005) 1.10
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke (2006) 1.10
Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord (2012) 1.07
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol (2006) 1.07
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol (2009) 1.06
Nonprescribed antimicrobial drugs in Latino community, South Carolina. Emerg Infect Dis (2005) 1.05
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials (2005) 1.02
Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord (2007) 1.01
Caffeine and progression of Parkinson disease. Clin Neuropharmacol (2008) 0.98
Factors influencing physician referrals of patients to clinical trials. J Natl Med Assoc (2008) 0.97
Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. J Virol Methods (2009) 0.96
Development and assay of RNA transcripts of enterovirus species A to D, rhinovirus species a to C, and human parechovirus: assessment of assay sensitivity and specificity of real-time screening and typing methods. J Clin Microbiol (2012) 0.95
Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain (2010) 0.95
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost (2005) 0.93
Minority enrollment in Parkinson's disease clinical trials. Parkinsonism Relat Disord (2008) 0.93
The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac hemodynamics, and plasma nitric oxide levels in acute stroke. J Stroke Cerebrovasc Dis (2007) 0.93
Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord (2009) 0.91
Addressing Issues Impacting Advanced Nursing Practice Worldwide. Online J Issues Nurs (2014) 0.91
Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J Stroke Cerebrovasc Dis (2007) 0.90
The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.90
A study of lower extremity amputation rates in older diabetic South Carolinians. J S C Med Assoc (2007) 0.89
Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol (2012) 0.89
Specific vs general cognitive remediation for executive functioning in schizophrenia: a multicenter randomized trial. Schizophr Res (2013) 0.88
Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke (2009) 0.86
Enrollment of racially/ethnically diverse participants in traumatic brain injury trials: effect of availability of exception from informed consent. Clin Trials (2014) 0.85
Dysconnection topography in schizophrenia revealed with state-space analysis of EEG. PLoS One (2007) 0.85
Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord (2009) 0.84
A pilot study of health education via a nurse-run telephone self-management programme for elderly people with osteoarthritis. J Telemed Telecare (2004) 0.83
Analysis of the visual system in Friedreich ataxia. J Neurol (2013) 0.83
Studying child abuse and neglect in Canada: we are just at the beginning. CMAJ (2003) 0.82
English language skills and diabetes and hypertension among foreign-born South Asian adults in England. Public Health Rep (2006) 0.82
Factor analysis of the Repeatable Battery for the Assessment of Neuropsychological Status. Appl Neuropsychol (2008) 0.82
An assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. J Clin Hypertens (Greenwich) (2004) 0.81
Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch Toxicol (2003) 0.80
Pitfalls in the quest of neuroprotectants for the perinatal brain. Dev Neurosci (2011) 0.80
Perceptions of diabetes among patients in an urban health care system. Ethn Health (2002) 0.80
Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study. PLoS Curr (2011) 0.79
Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord (2011) 0.79
A polytomous conditional likelihood approach for combining matched and unmatched case-control studies. Stat Med (2010) 0.79
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol (2015) 0.79
The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus. Am J Med Sci (2012) 0.78
Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care (2009) 0.78
An efficient multi-stage, single-arm Phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.77
Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. Cerebrovasc Dis (2015) 0.77
Lessons from adult stroke trials. Pediatr Neurol (2006) 0.77
Improving health outcomes in diverse and vulnerable populations: building on the experience of the Centers for Medical Treatment Effectiveness in Diverse Populations (MEDTEP). Ethn Health (2002) 0.77
Visual analysis of higher-order conjunctive relationships in multidimensional data using a hypergraph query system. IEEE Trans Vis Comput Graph (2013) 0.76
Damage-control resuscitation and emergency laparotomy: Findings from the PROPPR study. J Trauma Acute Care Surg (2016) 0.76
Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy. Clin Ther (2008) 0.76
Exercise in Heart Failure: A Synthesis of Current Research. Online J Knowl Synth Nurs (2000) 0.76
The incidence of ARDS and associated mortality in severe TBI using the Berlin definition. J Trauma Acute Care Surg (2016) 0.75
Association of transfusion red blood cell storage age and blood oxygenation, long-term neurologic outcome, and mortality in traumatic brain injury. J Trauma Acute Care Surg (2015) 0.75
Armoured brain. CMAJ (2003) 0.75
Prevention of shaken baby syndrome: Never shake a baby. Paediatr Child Health (2004) 0.75
Earlier Endpoints are Required for Hemorrhagic Shock Trials Among Severely Injured Patients. Shock (2017) 0.75